New Delhi: The Bharat Biotech developed-vaccine in collaboration with the Indian Council of Medical Research (ICMR) — Covaxin — has got the approval for the third phase of clinical trials.
The Hyderabad-based vaccine maker on October 2 had applied to the Drugs Controller General of India (DCGI) and sought permission to conduct Phase 3 trials.
According to official reports, a Central Drugs Standard Control Organisation’s (CDSCO) expert panel recommended following its assessment about safety and immunogenicity data of phase 1 and 2 clinical trials. This was sent to the Drugs Controller General of India (DCGI) for final approval.
In its application, the firm said that the study would cover around 28,500 subjects aged 18 years and above and would be conducted in 19 sites — including Delhi, Mumbai, Patna and Lucknow — across 10 states, according to news agency PTI.
Dubai: ODI cricket, Pakistan – they bring out the best in Virat Kohli. The Dubai… Read More
Cuttack: Three criminals were arrested by Choudwar police in Odisha’s Cuttack district for allegedly looting… Read More
Kolkata: Odisha FC fought gallantly in the lion’s den but finally returned empty-handed. Up against league… Read More
Kolkata: A West Bengal secondary board exam (Madhyamik) candidate recently took Artificial Intelligence (AI) to… Read More
New Delhi: A fourth batch of Indian nationals deported from the US arrived at Indira… Read More
Berhampur: Rushikulya river mouth in Odisha’s Ganjam district has emerged as a major rookery for… Read More
This website uses cookies.
